Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease

References

• Collaborators GBDCRD. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017;5(9):691–706. doi:10.1016/S2213-2600(17)30293-X28822787
   PubMed Web of Science ®Google Scholar
• World Health Organization. Projections of mortality and causes of death, 2016 to 2030. Available from: https://www.who.int/healthinfo/global_burden_disease/projections/en/ Accessed December 1, 2018.
   Google Scholar
• Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349(9064):1498–1504. doi:10.1016/S0140-6736(96)07492-29167458
   PubMed Web of Science ®Google Scholar
• Toy EL, Gallagher KF, Stanley EL, Swensen AR, Duh MS. The economic impact of exacerbations of chronic obstructive pulmonary disease and exacerbation definition: a review. COPD. 2010;7(3):214–228. doi:10.3109/15412555.2010.48169720486821
   PubMedGoogle Scholar
• Hilleman DE, Dewan N, Malesker M, Friedman M. Pharmacoeconomic evaluation of COPD. Chest. 2000;118(5):1278–1285. doi:10.1378/chest.118.5.127811083675
   PubMed Web of Science ®Google Scholar
• Kunisaki KM, Dransfield MT, Anderson JA, et al. Exacerbations of chronic obstructive pulmonary disease and cardiac events. A post hoc cohort analysis from the SUMMIT randomized clinical trial. Am J Respir Crit Care Med. 2018;198(1):51–57. doi:10.1164/rccm.201711-2239OC29442524
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Kunisaki KM, Strand MJ, et al. Acute exacerbations and lung function loss in smokers with and without chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;195(3):324–330. doi:10.1164/rccm.201605-1014OC27556408
   PubMed Web of Science ®Google Scholar
• Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. doi:10.1183/13993003.00214-201728182564
   PubMed Web of Science ®Google Scholar
• Kardos P, Mokros I, Sauer R, Vogelmeier CF. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA. Int J Chron Obstruct Pulmon Dis. 2018;13:1455–1468. doi:10.2147/COPD.S15982729765213
   PubMed Web of Science ®Google Scholar
• Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011;365(8):689–698. doi:10.1056/NEJMoa110462321864166
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa171390129668352
   PubMed Web of Science ®Google Scholar
• Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet. 2017;389(10082):1919–1929. doi:10.1016/S0140-6736(17)30188-528385353
   PubMed Web of Science ®Google Scholar
• Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet. 2016;388(10048):963–973. doi:10.1016/S0140-6736(16)31354-X27598678
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnacle H, Birk R, et al. FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2017;196(4):438–446. doi:10.1164/rccm.201703-0449OC28375647
   PubMed Web of Science ®Google Scholar
• Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1). Int J Chron Obstruct Pulmon Dis. 2016;11 Spec Iss:3–12. doi:10.2147/COPD.S8597626937185
   PubMedGoogle Scholar
• Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax. 2005;60(11):925–931. doi:10.1136/thx.2005.04052716055622
   PubMed Web of Science ®Google Scholar
• Au DH, Bryson CL, Chien JW, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2009;24(4):457–463. doi:10.1007/s11606-009-0907-y19194768
   PubMed Web of Science ®Google Scholar
• Sahin H, Varol Y, Naz I, Aksel N, Tuksavul F, Ozsoz A. The effect of pulmonary rehabilitation on COPD exacerbation frequency per year. Clin Respir J. 2018;12(1):165–174. doi:10.1111/crj.1250727240018
   PubMed Web of Science ®Google Scholar
• Criner GJ, Cordova FC, Furukawa S, et al. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999;160(6):2018–2027. doi:10.1164/ajrccm.160.6.990211710588623
   PubMed Web of Science ®Google Scholar
• Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med. 2003;348(21):2059–2073. doi:10.1056/NEJMoa03028712759479
   PubMed Web of Science ®Google Scholar
• Pompeo E, Rogliani P, Tacconi F, et al. Randomized comparison of awake nonresectional versus nonawake resectional lung volume reduction surgery. J Thorac Cardiovasc Surg. 2012;143(1):47–54, 54 e41. doi:10.1016/j.jtcvs.2011.09.05022056369
   PubMed Web of Science ®Google Scholar
• Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 mcg in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991. doi:10.1378/chest.13-157924385182
   PubMed Web of Science ®Google Scholar
• Donohue JF, Niewoehner D, Brooks J, O’Dell D, Church A. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res. 2014;15:78. doi:10.1186/1465-9921-15-7825015176
   PubMed Web of Science ®Google Scholar
• Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet. 2009;374(9691):685–694. doi:10.1016/S0140-6736(09)61255-119716960
   PubMed Web of Science ®Google Scholar
• Rennard SI, Calverley PM, Goehring UM, Bredenbroker D, Martinez FJ. Reduction of exacerbations by the PDE4 inhibitor roflumilast–the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18. doi:10.1186/1465-9921-12-12221272339
   PubMed Web of Science ®Google Scholar
• Saha S, Brightling CE. Eosinophilic airway inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2006;1(1):39–47.18046901
   PubMedGoogle Scholar
• Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med. 2012;186(1):48–55. doi:10.1164/rccm.201108-1553OC22447964
   PubMed Web of Science ®Google Scholar
• Couillard S, Larivee P, Courteau J, Vanasse A. Eosinophils in COPD exacerbations are associated with increased readmissions. Chest. 2017;151(2):366–373. doi:10.1016/j.chest.2016.10.00327746201
   PubMed Web of Science ®Google Scholar
• Leigh R, Pizzichini MM, Morris MM, Maltais F, Hargreave FE, Pizzichini E. Stable COPD: predicting benefit from high-dose inhaled corticosteroid treatment. Eur Respir J. 2006;27(5):964–971. doi:10.1183/09031936.06.0007210516446316
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Davies L, Calverley PM, Aaron SD, Brightling CE, Pavord ID. Blood eosinophil guided prednisolone therapy for exacerbations of COPD: a further analysis. Eur Respir J. 2014;44(3):789–791. doi:10.1183/09031936.0006261424925917
   PubMed Web of Science ®Google Scholar
• Martinez FJ, Rabe KF, Calverley PMA, et al. Determinants of response to roflumilast in severe chronic obstructive pulmonary disease. Pooled analysis of two randomized trials. Am J Respir Crit Care Med. 2018;198(10):1268–1278. doi:10.1164/rccm.201712-2493OC29763572
   PubMed Web of Science ®Google Scholar
• Kolsum U, Damera G, Pham TH, et al. Pulmonary inflammation in patients with chronic obstructive pulmonary disease with higher blood eosinophil counts. J Allergy Clin Immunol. 2017;140(4):1181–1184 e1187. doi:10.1016/j.jaci.2017.04.02728506852
   PubMed Web of Science ®Google Scholar
• Tashkin DP, Wechsler ME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349. doi:10.2147/COPD.S15229129403271
   PubMed Web of Science ®Google Scholar
• Hastie AT, Martinez FJ, Curtis JL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-029146301
   PubMed Web of Science ®Google Scholar
• Singh D, Kolsum U, Brightling CE, et al. Eosinophilic inflammation in COPD: prevalence and clinical characteristics. Eur Respir J. 2014;44(6):1697–1700. doi:10.1183/09031936.0016241425323230
   PubMed Web of Science ®Google Scholar
• Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012;380(9842):651–659. doi:10.1016/S0140-6736(12)60988-X22901886
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa140329025199059
   PubMed Web of Science ®Google Scholar
• Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014;371(13):1189–1197. doi:10.1056/NEJMoa140329125199060
   PubMed Web of Science ®Google Scholar
• Yancey SW, Ortega HG, Keene ON, et al. Meta-analysis of asthma-related hospitalization in mepolizumab studies of severe eosinophilic asthma. J Allergy Clin Immunol. 2017;139(4):1167–1175 e1162. doi:10.1016/j.jaci.2016.08.00827726946
   PubMed Web of Science ®Google Scholar
• Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017;5(5):390–400. doi:10.1016/S2213-2600(17)30125-X28395936
   PubMed Web of Science ®Google Scholar
• Liu LY, Mathur SK, Sedgwick JB, Jarjour NN, Busse WW, Kelly EA. Human airway and peripheral blood eosinophils enhance Th1 and Th2 cytokine secretion. Allergy. 2006;61(5):589–597. doi:10.1111/j.1398-9995.2006.01060.x16629789
   PubMed Web of Science ®Google Scholar
• Possa SS, Leick EA, Prado CM, Martins MA, Tiberio IF. Eosinophilic inflammation in allergic asthma. Front Pharmacol. 2013;4:46. doi:10.3389/fphar.2013.0004623616768
   PubMed Web of Science ®Google Scholar
• Pazdrak K, Stafford S, Alam R. The activation of the Jak-STAT 1 signaling pathway by IL-5 in eosinophils. J Immunol. 1995;155(1):397–402.7602114
   PubMed Web of Science ®Google Scholar
• Sano M, Leff AR, Myou S, et al. Regulation of interleukin-5-induced beta2-integrin adhesion of human eosinophils by phosphoinositide 3-kinase. Am J Respir Cell Mol Biol. 2005;33(1):65–70. doi:10.1165/rcmb.2005-0076OC15802551
   PubMed Web of Science ®Google Scholar
• Keating GM. Mepolizumab: first global approval. Drugs. 2015;75(18):2163–2169. doi:10.1007/s40265-015-0513-826603873
   PubMed Web of Science ®Google Scholar
• Tan LD, Bratt JM, Godor D, Louie S, Kenyon NJ. Benralizumab: a unique IL-5 inhibitor for severe asthma. J Asthma Allergy. 2016;9:71–81. doi:10.2147/JAA.S7804927110133
   PubMed Web of Science ®Google Scholar
• Rothenberg ME, Klion AD, Roufosse FE, et al. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med. 2008;358(12):1215–1228. doi:10.1056/NEJMoa07081218344568
   PubMed Web of Science ®Google Scholar
• Roufosse FE, Kahn JE, Gleich GJ, et al. Long-term safety of mepolizumab for the treatment of hypereosinophilic syndromes. J Allergy Clin Immunol. 2013;131(2):461–467e461–465. doi:10.1016/j.jaci.2012.07.055
   Web of Science ®Google Scholar
• Simon HU, Plotz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341(15):1112–1120. doi:10.1056/NEJM19991007341150310511609
   PubMed Web of Science ®Google Scholar
• Roufosse F, Cogan E, Goldman M. Lymphocytic variant hypereosinophilic syndromes. Immunol Allergy Clin North Am. 2007;27(3):389–413. doi:10.1016/j.iac.2007.07.00217868856
   PubMed Web of Science ®Google Scholar
• Schwartz RS. The hypereosinophilic syndrome and the biology of cancer. N Engl J Med. 2003;348(13):1199–1200. doi:10.1056/NEJMp03001912660383
   PubMed Web of Science ®Google Scholar
• Gallagher MP, Kelly PJ, Jardine M, et al. Long-term cancer risk of immunosuppressive regimens after kidney transplantation. J Am Soc Nephrol. 2010;21(5):852–858. doi:10.1681/ASN.200910104320431040
   PubMed Web of Science ®Google Scholar
• Vial T, Descotes J. Immunosuppressive drugs and cancer. Toxicology. 2003;185(3):229–240.12581698
   PubMed Web of Science ®Google Scholar
• Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377(17):1613–1629. doi:10.1056/NEJMoa170820828893134
   PubMed Web of Science ®Google Scholar
• Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials. Lancet Respir Med. 2013;1(3):210–223. doi:10.1016/S2213-2600(13)70040-724429127
   PubMed Web of Science ®Google Scholar
• Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009;360(10):985–993. doi:10.1056/NEJMoa080543519264687
   PubMed Web of Science ®Google Scholar
• Review IfCaE. Biologic Therapies for Treatment of Asthma Associated with Type 2 Inflammation: Effectiveness, Value, and Value-Based Price Benchmarks. Available from: https://icer-review.org/wp-content/uploads/2018/04/Asthma-Revised-Report-FOR-PUBLICATION-11.13.2018.pdf. Accessed December 1, 2018.
   Google Scholar
• GSK reports on outcome of the FDA advisory committee on mepolizumab for the treatment of COPD patients on maximum inhaled therapy. Available from: https://www.gsk.com/en-gb/media/press-releases/gsk-reports-on-outcome-of-the-fda-advisory-committee-on-mepolizumab-for-the-treatment-of-copd-patients-on-maximum-inhaled-therapy/. Accessed December 1, 2018.
   Google Scholar
• Brightling CE, Bleecker ER, Panettieri RA Jr., et al. Benralizumab for chronic obstructive pulmonary disease and sputum eosinophilia: a randomised, double-blind, placebo-controlled, phase 2a study. Lancet Respir Med. 2014;2(11):891–901. doi:10.1016/S2213-2600(14)70187-025208464
   PubMed Web of Science ®Google Scholar
• AstraZeneca. Efficacy and safety of benralizumab in moderate to very severe chronic obstructive pulmonary disease (COPD) with exacerbation history (TERRANOVA). Available from: https://clinicaltrials.gov/ct2/show/NCT2155660NLMidentifier:NCT2155660 Accessed 121, 2018.
   Google Scholar
• AstraZeneca. Benralizumab efficacy in moderate to very severe chronic obstructive pulmonary disease (COPD) with exacerbation history (GALATHEA). Available from: https://clinicaltrials.gov/ct2/show/NCT2138916NLMidentifier:NCT2138916 Accessed 121, 2018.
   Google Scholar